Metraipolis › archive › dc_ce9c96199ffe

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial — Europe PMC PMID:41590377

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41590377
DOI
10.3390/curroncol33010057
License (as archived)
solo-consultazione
Archived
2026-11-06T17:36:10.494Z
SHA-256 of the archived text
ed31e8d8f5d2913462b9e38ca821a7f53547d16ae620fdbf5c83f05809bcaf4a
Stable URL of this page
https://metraipolis.com/documento/dc_ce9c96199ffe

How to cite

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial — Europe PMC PMID:41590377 — Europe PMC (en), https://europepmc.org/article/MED/41590377 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ce9c96199ffe (Metraipolis archive dc_ce9c96199ffe, sha256 ed31e8d8f5d2913462b9e38ca821a7f53547d16ae620fdbf5c83f05809bcaf4a)
BibTeX
@misc{dcce9c96199ffe,
  title = {Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial — Europe PMC PMID:41590377},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41590377},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ce9c96199ffe; sha256 ed31e8d8f5d2913462b9e38ca821a7f53547d16ae620fdbf5c83f05809bcaf4a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41590377. Agents can read the archived copy with the MCP tool read_document.